Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer
Authors:
- 12 July 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 10286-10296
Abstract
The neurotrophic receptor tyrosine kinase (NTRK) genes including NTRK1, NTRK2, and NTRK3 encode the tropomyosin receptor kinase (Trk) proteins TrkA, TrkB, and TrkC, respectively. So far, two TRK inhibitors, larotrectinib sulfate (LOXO-101 sulfate) and entrectinib (NMS-E628, RXDX-101), have been approved for clinical use in 2018 and 2019, respectively. To overcome acquired resistance, next-generation Trk inhibitors such as selitrectinib (LOXO-195) and repotrectinib (TPX-0005) have been developed and exhibit effectiveness to induce remission in patients with larotrectinib treatment failure. Herein, we report the identification and optimization of a series of macrocyclic compounds as potent pan-Trk (WT and MT) inhibitors that exhibited excellent physiochemical properties and good oral pharmacokinetics. Compound 10 was identified via optimization from the aspects of chemistry and pharmacokinetic properties, which showed good activity against wild and mutant TrkA/TrkC in in vitro and in vivo studies.Keywords
Funding Information
- Shandong Province (2017WS691, 2019KJM009, 2020KJM003)
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China (82073888)
This publication has 17 references indexed in Scilit:
- Larotrectinib (LOXO-101)2018
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenNew England Journal of Medicine, 2018
- Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsMolecular Cancer Therapeutics, 2016
- NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesESMO Open, 2016
- TRKing Down an Old Oncogene in a New Era of Targeted TherapyCancer Discovery, 2015
- The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionMolecular Oncology, 2014
- Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number dataBMC Genomics, 2013
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- Rearrangements of NTRK1 gene in papillary thyroid carcinomaMolecular and Cellular Endocrinology, 2010
- The impact of translocations and gene fusions on cancer causationNature Reviews Cancer, 2007